Left ventricular assist device support with a centrifugal pump for 2 months in a 5-kg child

Takafumi Inoue1, Takashi Nishimura, Arata Murakami

  • 1Department of Cardiothoracic Surgery, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan. takainoue-tky@umin.ac.jp

Insights

Left ventricular assist device (LVAD) support for infants under 5kg remains challenging. This case report details successful 2-month centrifugal pump support in a 4-month-old infant with dilated cardiomyopathy, highlighting potential for mid-term mechanical circulatory support.

Area of Science:

  • Pediatric Cardiology
  • Mechanical Circulatory Support
  • Cardiothoracic Surgery

Background:

  • Left ventricular assist device (LVAD) implantation outcomes in small children, especially those under 5kg, are often unsatisfactory.
  • Mid-term and long-term mechanical support for pediatric heart failure remains a significant clinical challenge.
  • Existing LVADs designed for pediatric use have limitations for very low-body-weight infants.

Observation:

  • A 4-month-old infant diagnosed with dilated cardiomyopathy (DCM) required mechanical circulatory support.
  • Extracorporeal centrifugal pump (ROTAFLOW®) support was initiated for 2 months in this low-body-weight infant.
  • The infant experienced acceptable control of thrombosis during the support period.

Findings:

  • This case represents the first report of successful 2-month LVAD support using a centrifugal pump in a child weighing under 5kg.
  • Autopsy confirmed no significant thrombosis in the device components or cardiac chambers.
  • The infant ultimately succumbed to sepsis, not device-related thrombosis.

Implications:

  • Successful mid-term mechanical support with a centrifugal pump is feasible in extremely low-body-weight infants with severe heart failure.
  • This approach may offer a viable option for pediatric patients awaiting heart transplantation or recovery.
  • Further research and device development are warranted to improve long-term outcomes and reduce complications like sepsis in pediatric LVAD support.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...